Exploring barriers to commercial peanut oral immunotherapy treatment during COVID-19.

Leef, Chelsea; Horton, Codi; Lee, Tricia; Lee, Gerald; Tison, Katherine; Vickery, Brian P

Leef, Chelsea; Horton, Codi; Lee, Tricia; Lee, Gerald; Tison, Katherine; Vickery, Brian P.

Leef C; Children's Healthcare of Atlanta, Atlanta, Ga.
Horton C; Children's Healthcare of Atlanta, Atlanta, Ga.
Lee T; Children's Healthcare of Atlanta, Atlanta, Ga; Emory University School of Medicine, Atlanta, Ga.
Lee G; Children's Healthcare of Atlanta, Atlanta, Ga; Emory University School of Medicine, Atlanta, Ga.
Tison K; Emory University School of Medicine, Atlanta, Ga.
Vickery BP; Children's Healthcare of Atlanta, Atlanta, Ga; Emory University School of Medicine, Atlanta, Ga. Electronic address: brian.vickery@gmail.com.

J Allergy Clin Immunol Pract ; 10(1): 309-311.e1, 2022 01.

Article in English | MEDLINE | ID: covidwho-1509922

Subject(s)

COVID-19; Peanut Hypersensitivity; Administration, Oral; Allergens; Arachis; Desensitization, Immunologic; Humans; Immunotherapy; SARS-CoV-2

Fulltext

XML

PubMed Links

Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Peanut Hypersensitivity / COVID-19 Limits: Humans Language: English Journal: J Allergy Clin Immunol Pract Year: 2022 Document Type: Article Affiliation country: J.jaip.2021.08.044

Similar

MEDLINE

LILACS

LIS

Fulltext

XML

PubMed Links

Search on Google